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ABSTRACT
Genome engineering relies on DNA modifying enzymes that are able to locate a 
DNA sequence o f interest and initiate a desired genome rearrangement. Currently, the 
field predominantly utilizes site-specific DNA nucleases that depend on the host DNA 
repair machinery to complete a genome modification task. We show here that genome 
engineering approaches that employ self-sufficient, versatile site-specific DNA 
recombinase Flp and Cre can be developed into promising alternatives. We demonstrate 
that a Flp variant evolved to recombine an FRT-like sequence FL-IL10A, which is located 
upstream of the human interleukin-10 gene, can target this sequence in the model setting 
and native HEK293 cells. Similarly, Cre variant evolved to recombine at loxP-like 
sequence LL-69058, which is located upstream of the beta globin gene, can target this 
sequence in the model setting of CHO cells and human HEK293 cells.
The target-specific Flp variant is able to perform the integration reaction but the 
efficiency of the integration reaction in human cells can be enhanced by ‘humanizing’ the 
Flp variant gene and by adding the NLS sequence to the recombinase. Cre variant 
displays a poor replacement activity in the mammalian cells and thus is fused with TAL 
DNA-binding domain to enhance their performance. TAL-Cre variant is able to perform 
efficient replacement reaction, when paired with another recombinase (dual RMCE). The 
Cre variant replacement activity is observed only when they are fused to the TAL
DNA-binding domain. The TAL-Cre fusion has higher replacement efficiency compared 
to no replacement activity with just Cre variant.
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CHAPTER 1
INTRODUCTION
1.1 Background
Human genetic disorders are caused by abnormalities in the genome which are 
then passed to offspring. Some of the genetic disorders that are caused by mutation in a 
single gene include sickle cell disease (SCD), cystic fibrosis, neurofibromatosis (NF), 
Tay-Sachs disease, Duchenne muscular dystrophy (DMD) and platelet type bleeding 
disorder as well as many others. Gene therapy is hoped to cure genetic disorders by 
adding the wild type gene or replacing the mutated gene with a wild type gene, restoring 
proper function in the cells. Initially, viral vectors were used as gene delivery vehicles but 
this approach poses potential risk o f inserting the vector randomly in the genome, 
potentially activating the tumor promoting pathways. An alternative to viral vector based 
gene therapy could be the correction o f the mutated gene using site-specific 
recombinases. These enzymes have been shown to integrate, excise, invert genes, and 
replace gene fragments in mammalian cells.
My research aims to use site-specific recombinases for integration and 
replacement of genes in the human genome with the goal of curing a genetic disease. 
Recombinases bind to specific DNA sequences called recombination targets and catalyze 
DNA rearrangement. For example, integrase from the bacteriophage lambda, specific to 
attP and attB target sequences, catalyze integration of the viral genome into the bacterial
1
2chromosome. XerCD from the Escherichi coli is specific to the dif target sequence in the 
bacterial genome and also dif-like target sequences cer (plasmid ColEl), and psi (plasmid 
SC 101) sites. XerCD plays an important role by resolving chromosome and plasmid 
dimers. Cre recombinase from bacteriophage PI, specific to the loxP target sequence, 
catalyzes the circularization o f linear phage genomes. Flp recombinase that is encoded by 
a 2 micron plasmid from Saccharomyces cerevisiae and is specific for the FRT  target 
sequence, helps in maintaining the plasmid copy number by inverting one part o f the 2 
micron plasmid relative to the other part during replication [1-4].
Site-specific tyrosine recombinases are primarily found in the prokaryotes, but 
they have also been found in the archaea and some eukaryotes. PSI-BLAST, a computer 
software, identifies more than 1000 related sequences of the tyrosine recombinase family 
[3,4]. Therefore, the 3D fold of tyrosine site specific recombinases is adapted to 
recognize a wide variety of target sequences. This phenomenon can be exploited to 
evolve recombinase variants that recognize target-like sequences that resemble the native 
target sequences. Such target-like sequences for a recombinase can be found in the 
human genome on average every 5000 bp (5 kb) [5], For the purpose o f gene therapy, 
target-like sequences can be used as recombination targets to either integrate or replace a 
gene region.
Recombinases can be used as tools for genome manipulation. In principle, 
recombinases can be altered to recognize target-like sequences using directed evolution 
approaches that include a combination of several techniques: DNA shuffling, PCR 
mutagenesis and error prone PCR. The quest to generate variants o f tyrosine 
recombinases with desired target specificity began when several mutant and chimeric X
3integrase variants were shown to recombine target sites for HK.022 integrase [4,5]. The 
research was boosted by the advances in two molecular evolution techniques: error-prone 
PCR and DNA shuffling which allow for the fast generation of recombinase variant 
libraries [6-8]. The solved structures o f the CrdloxP  and Flp/FRT  complexes [7,8] 
provided another boost: they helped utilize another molecular evolution technique, site- 
directed mutagenesis of amino acids that can affect DNA binding so that they can bind to 
the target-like sequences efficiently.
For this project, I will focus on two o f the approximately 600,000 recombinase 
target-like sequences. One of the target-like sequences (FL-IL10A) is located in the 
interleukin gene on chromosome 1 (Figure 1.1). The second target-like sequence (LL- 
69058) is located in the beta-globin gene on chromosome 11 (Figure 1.2). These target­
like sequences resemble the FRT  and loxP sequences, respectively. The long term goal of 
my project is to evolve and test the Flp and Cre recombinase variants specific for these 
target-like sequences.
Figure 1.2: Relative locations of LL-69058, FL-71362 and E6V (Glu to Val) 
mutation.
FL-EL10A chromosome 1 
______AA
IL10 gene
Figure 1.1: Relative location of the FL-1L10A sequence.
Glu to Val
GAG to GTG
LLi FL 71362 chromosome 11 
_ / \ Z X  
HBB gene
41.2 Objectives
The objectives for my research project are as follows:
1. Test variants o f Flp recombinase that can target FRT-like sequence FL-IL10A 
from the human interleukin (IL10) gene in mammalian cells (Figure 1.1).
2. Evolve and test variants o f Cre recombinase that can target loxPA ike sequence 
LL-69058 from the human beta globin (HBB) gene in mammalian cells (Figure 1.2).
1.3 Hypotheses
1. Flp recombinase variants functionally tested in E.coli can integrate a vector 
into FL-IL10A in mammalian cells. (Figure 1.1)
2. Cre recombinase variants can be evolved in E.coli to recognize LL-69058 and 
functionally tested in mammalian cells to replace a gene cassette when paired with 
evolved Flp recombinase variants specific to FL-71362. (Figure 1.2)
1.4 Literature Review
1.4.1 Conservative Site Specific Recombination
and Types of Recombinases
Site-specific recombinases are actively used in mammalian cells to engineer genes 
and chromosomes. These recombinases can delete, insert, or invert a gene cassette 
flanked by the recombinase target sequences resulting in activating or silencing the gene 
cassette [11].
Site-specific recombination leads to DNA rearrangement at specific sequences 
called the recombination target (RT) sequences [12]. "Conservative" site-specific 
recombination means that there is no loss or addition of nucleotides at the time o f DNA 
rearrangement [13]. Recombinases were discovered in bacteria, temperate phages, and
5yeast where they exist to perform various events like resolution, inversion and 
integration. Conservative site specific recombination was discovered by Allan Campbell 
in 1968 during his studies o f bacteriophage lambda and its host bacterium E.coli [14].
Site-specific recombinases function on the principle o f strand breakage and 
rejoining and the recombination is divided into several steps. In general, the recombinase 
catalyzes cleavage, strand exchange, and rejoining of the DNA within the synaptic 
complex to obtain recombined products [4], The recombinase binds to the two 
recombinase target sequences forming a synaptic complex. The core target sequence 
consists of two inverted repeat sequences flanking a spacer or crossover region [15]. 
Depending on the recombination mechanism, the requirement for accessory proteins, 
recognition o f target sequence and strand exchange at the target sequences, recombinases 
are divided into two families: serine (Resolvases/Invertases) and tyrosine (Integrases) 
recombinases [2,9,13] (Table 1.1).
6Table 1.1: Examples of recombinases from serine and tyrosine family and their 
biological functions [2,9,12-14].
Tyrosine Recombinase
Invertase
Integrase
B i o l o g i c a l  F u n c t i o n
X-Integrases Integration and excision
XerC/D Excision and resolution
Flp Inversion and resolution
Cre Excision
Int i Integration and excision
XisA/XisC Excision
FimB, FimE Inversion
Int of Tn916/Tn 1545 Integration and excision
Serine Recombinase
Resolvase
Some recombinases belonging to the Invertase and Integrase family have 
accessory binding sites for expression of enhancer elements away from crossover regions 
(synapse) [17]. The orientation of target sequences and the location of the enhancer 
sequences for some recombinases are shown in Figure 1.3.
7S ite P ro te in
FlpFRT
loxP Cre
attB Int
A
- 0 - 0
0 ^ 0
¥ 4  K
Int
glx,hlx Gin, Hin
res Resolvase
Figure 1.3: Target sequences for conservative site-specific recombinase families.
The brown rectangular box represents the binding target sequence and the inverted 
arrows represent the orientation of the target sequence. The circle (A) represent the 
accessory site away from the target sequence express the enhancer elements [14].
1.4.1.1 Serine Recombinase Family. Serine residues play a major role as a 
conserved amino acid that attacks the DNA and covalently links to the DNA during 
strand exchange. The Serine recombinase family is sub-divided into groups based on 
performance o f different recombination events like resolution, inversion, and integration. 
The major groups of this family are Resolvases (Tn3, y8), Invertases (Hin, Gin, Cin), and 
Integrases (<j>C31) (Table 1.1). The Tn3 resolvase, mobile genetic elements called 
transposons found in prokaryotes, require two 28 bp res sequence in direct repeat and six 
resolvase dimers to form a fully active synapse. The <j)C31 integrases interact with DNA 
attachment sequences called phage attP and bacterial attB sequences to give recombinant 
products. These attachment sites favor the integration of phage genome into the E.coli 
genome forming hybrid attL and attR attachment sites. The attP and attB sequences are 
39 bp and 34 bp in length, respectively. Evolved <|>C31 integrases are often used as a tool 
to manipulate the human genome [2]. When <|>C31 are linked to zinc finger nucleases, 
they exhibit rapid genome engineering strategies to recombine at specific loci in the
8human cells or non-human origin cells [18]. The invertase recombinases like the Gin that 
recognize gix, Hin that recognize hix (Figure 1.4) require invert repeats of sequence to 
give recombinant products.
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B --------------------------►
5 - - - TTCTTGAAAACCA£|GGTTTTTGATAA 
3 - - - AAQAACTTTTQQffTCCAAAAACTATT
Figure 1.4: Serine recombinase target sequence for invertase family indicating 
location of accessory sites that express enhancer proteins (A) and target sequence of 
Hin recombinase (B). The inverted arrows show the orientation of hix target 
sequence [1].
The Ser residue located in the catalytic domain of serine recombinase cleaves the 
phosphodiester bond of DNA on all four strands producing a 3'-hyroxyl end and 5'- 
phosphoserine linkage ends as intermediate products [10,15]. In the process of strand 
exchange a structural complex called a synapse is formed. The enzyme-DNA complex is 
rotated and ligated to obtain recombines DNA (Figure 1.5).
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Figure 1.5: Schematic representation of strand exchange mediated by serine 
recombinase [19].
This conserved region contributes to the active site of the recombinase. The C- 
rotated and ligated to obtain recombined DNA (Figure 1.5). terminal helix-tum-helix 
(HTH) domain of serine recombinases contain highly conserved residues. The N-terminal 
catalytic domain consists of at least 10 highly conserved residues including three cysteine 
and non-conserved residues rich in leucine/isoleucine/valine/methionine [1]. The 
conserved residues of invertase family Hin recombinase (which are Fis dependent) are 
Glnl51, Argl54 and Leul55, which directly or indirectly interact with Fis. Any mutation 
in the residues can inactivate Hin. y8 resolvase has conserved residues at positions Lys54 
and Glu56 which participate in protein-protein interaction between cut DNA strands 
(Figure 1.6) [17].
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Figure 1.6: Sequence alignment of DNA Binding Domains of helix a l and helix aB 
region of invertases and resolvases members belonging to the serine recombinase 
family [17]. The number at the start of the sequence indicates the position of the 
first residue and so on. The red rectangular box indicates the important conserved 
residues.
The synaptic complex for serine recombinase forms only when the DNA is 
negatively supercoiled. The invertase group of serine recombinase requires accessory 
proteins for their activity. The Fis/enhancer system acts as accessory proteins and 
controls the DNA cleavage and exchange [17]. The system is encoded by a sequence 
region called an accessory sequence located away from the crossover sequence [15,17] 
(Figure 1.5).
Zinc finger nucleases (ZFN) and TALE DNA-binding domains can be adapted to 
recognize genomic target sequences. By engineering the ZFN and TALE binding
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specificity and reducing or altering the residue in the serine recombinase structure to 
recognize the genomic target sequences it can help increase the application of evolved 
recombinases.
1.4.1.2 Tyrosine Recombinase Family. Tyrosine recombinase families are called so 
because the tyrosine residue plays a major role as a conserved amino acid that attacks the 
DNA and covalently links to the DNA during strand exchange. The tyrosine residue 
attacks the phosphodiester bond on DNA producing 3' phosphotyrosyl intermediate.
Some members of the tyrosine family include Flp, Cre, ^-Integrase, Xerc/D and Int I 
(Table 1.1). They can perform recombination events such as excision, integration, 
resolution and replacement.
Other examples o f tyrosine recombinase family members are Int recombinase 
which recognizes the attP and attB site, Cre recombinase that recognizes the loxP site, 
and Flp recombinase that recognizes the FRT site [11,20]. Figure 1.10 indicates the target 
sequences loxP and FRT for Cre and Flp recombinases. The target sequences for 
recombinases are composed of 6-8 bp spacer regions flanked on either side by 13-14 bp 
inverted repeats [3,11,20-22]. Change in the bases o f the target sequence can render the 
recombinase incapable of recognizing it [11,20,22].
Tyrosine recombinase binds to the target sequence (bringing sites together) 
resulting in a highly structured complex called a synapse. In the complex, a pair of strand 
exchanges occurs which proceed to an intermediate called a Holliday junction 
(Figure 1.7).
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exchangeyg y^ jl exchange second pair
Holliday intermediate
Figure 1.7: Schematic representation of strand exchange mediated by tyrosine 
recombinase [19].
The Holliday junction is resolved when the second pair strand exchange occurs 
forming recombined products [10,23,24], Tyrosine recombinase on cleaving the DNA 
strand, produces a 5'-hydroxyl end and 3'-phosphotyrosine ends [10,24,25]. For 
tyrosinerecombinase, there should always be sequence homology at the spacer region/ 
crossover region for recombination to occur. The catalytic domain of tyrosine 
recombinase has four conserved residues located at the C-terminal of the protein (Arg- 
His-X-X-Arg-Tyr) and form the RHR traid (Argl91, His305 and Arg308) in Flp 
[10,12,21,25,26], (Figure 1.8). The RHR triad is responsible for the orientation o f the 
phosphodiester bonds in the recombination steps [12,26].
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Figure 1.8: Conserved residues of Flp and Cre recombinase in the C-terminal 
domain. The tyrosine residing at position 343 in Flp and 324 in Cre in the 
catalytic site play a vital role in DNA cleavage [27],
Depending on the location and relative orientation of their targets, tyrosine 
recombinase variants can mediate insertions, deletions, replacements and translocations 
o f DNA fragments. Moreover, site-specific recombinases were shown to perform genetic 
rearrangements in all cell types tested, from bacteria to plant to human [28,29],
Integration and excision are reversible processes where target sequences are located 
on different DNA strands. In Figure 1.9.A, the circular molecule can integrate into the 
genome and can be excised from the genome. Resolution yields a circular DNA 
plasmid into two small circular molecules. Two target sequences are located on the 
plasmid in the same orientation (Figure 1.9.B). In the inversion reaction, the two 
oppositely oriented target sequences flip the region between them (Figure 1.9.C). In MCE, 
or replacement, the gene cassette is exchanged between two genomes or chromosomes in 
(Figure 1.9.D)
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Figure 1.9: Different types of recombination reactions catalyzed by recombinases.
A.) Excision and insertion of DNA in the genome at site-specific target sequence.
B.) A circular DNA molecules resolving in two small circular DNA molecules by 
recombining at the target sites. C.) Inversion of DNA occurs when the target 
sequences are present in opposite directions. D.) RMCE (Recombinase Mediated 
Cassette Exchange) causes replacement of gene cassette which is flanked on either 
side with target sequences on two DNA strands.
1.4.1.2.A Cre Recombinase. Cre (cyclization recombinase) recombinases from the 
bacteriophage PI were used for the first time in mammalian cells by Sauer in 1989 [30]. 
Cre recombinases perform two functions, circularization of linear DNA via the crossing 
over loxP, and resolution of dimers [20]. This recombinase does not require any 
accessory proteins and can perform recombination independently [23,31]. Cre 
recombinases bind specifically and efficiently at specific target sequences called loxP
sites (Figure 1.10).
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•13 -11 -9  -7 -5 -3 -1 3 5 7 9 11 13
ATAACTTCGTATAA t g t a t g  CTATACGAAGTTAT 
TATTGAAGCATATT acatac.GATATGCTTCAATAT
FRT
GAAGTTCCTATAC t t t c t a g a  GAATAGGAACTTC 
CTTCAAGGATATG aaa CTTATCCTTGAAG
Figure 1.10: loxP and FRT target sequence with 6bp and 8bp spacer flanked with 
13-14 bp invert repeats respectively. The inverted arrows indicate the inverted 
repeats with spacer region located between them. The small arrows point at the 
region of crossing over when recombinase binds to the inverted repeats. The 
numbers above the big arrows indicate the location of the bases that vary from 
13-14 bp.
1.4.1.2.B Flp Recombinase. Flp recombinase is encoded in the 2pm plasmid of the 
yeast Saccharomyces cerevisiae and recognizes a specific target sequence called FRT 
(Flp Recombination Target) (Figure 1.9). Evans et al, in 1990, discovered that the 
tyrosine residue at position 343 in the Flp is responsible for its catalytic function but does 
not help in substrate recognition [32]. In yeast, Flp recombinases are responsible for 
preserving a high plasmid copy number [20].
Cre and Flp tyrosine recombinases have been widely used as tools for genome 
engineering. When these recombinases are evolved using directed evolution techniques to 
recognize the target sequences, it opens many new areas of genome manipulation to cure 
various diseases. The activity o f the recombinases can be enhanced further by fusing
-13 -11 -9  -7 3 5 7 9 11 13
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them to DNA binding domains of zinc-finger nucleases and TALE. CR1SPR technology 
has also been utilized to guide the delivery o f particular genes to desired destinations in 
the genome.
1.4.2 Evolution of Cre and Flp Tyrosine Recombinase Using 
Directed Evolution Techniques
In nature, living organisms undergo strict condition constraints that force them to 
evolve at the DNA level by inducing mutations in their structure. These mutations can be 
beneficial or harmful based on the survival of the organism. It takes several generations 
for the beneficial mutations to express in their genome. This phenomenon of introducing 
mutations can be applied in the laboratory and be used to enhance the property o f a 
particular protein, which can result in improving the yield, or increasing the efficiency of 
an enzyme or particular pathway. DNA mutagenesis and DNA shuffling are the mostly 
widely used laboratory techniques for evolving a particular protein.
DNA mutagenesis can be performed in two different ways, depending on the 
knowledge of the protein structure. They are classified as random evolution technique 
and targeted evolution technique.
1.4.2.1 Random Evolution
1.4.2.1.1 Error-prone PCR. Error prone PCR or PCR mutagenesis was first 
discovered by Leung, et al in 1989 [33], The protocol was modified by Cadwell and 
Joyce in 1992 [34], Random mutations were introduced in the gene fragment by altering 
regular PCR conditions (Figure 1.11).
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Figure 1.11: Diagrammatic representation of Cyclic Mutagenesis or Error Prone 
PCR, causing introduction of random mutations.
The parameters altered in the reaction include: (1) increasing the concentration of 
Taq polymerase; (2) increasing extension time; (3) increasing concentration o f MgCl2+; 
(4) addition of 0.5mM MnCl2+ and (5) increasing ImM concentration of GTP, CTP, TTP 
and 0.2mM ATP. Parameters o f steps 4 and 5 have higher chances o f introducing random 
mutation. The goal behind altering the PCR reaction parameter was to reduce the fidelity 
of amplifying the gene fragment [33].
1.4.2.1.2 DNA Shuffling. DNA shuffling, an evolution technique, randomly 
introduces mutations (insertion, deletion, or change in the codon) in the protein structure. 
Stemmer was the first to discover the technique o f DNA shuffling, where he began with 
shuffling the LacZ gene to observe changes in the P-lactamase pathway [8]. The 
procedure, as shown in Figure 1.12, involves shuffling of two or more homologus genes 
with different mutations or allele genes. The genes are digested with DNAse, resulting 
into fragmentation o f the genes. Overlapping ends are produced upon digestion as 
DNAse makes random cuts in the gene. Small fragments o f the digested gene are 
observed on the gel. The gene fragments are assembled in a PCR reaction to reform the 
original gene.
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The overlapping ends act as primers to anneal the fragments together. During this 
PCR, in the absence o f a primer, random mutations are introduced into the gene 
fragment. The last step involves the use of specific forward and reverse primers to 
amplify the whole gene. The PCR mix is a library of different recombined genes having 
different mutations. The mutations are usually additive enhancing the property o f the 
protein or enzyme. Screening of the gene pool for their activity can help in narrowing 
down to the best possible variant which has much better activity than the original genes 
used for shuffling [8].
DNase
Gene 1 Gene 2
•  ------- r -    •
Digestion at random 
sitesleading to small 
fragments
The two gene fragments are 
mixed and amplified using 
\ I specific primers
Recombinant genes 
DNA Shuffling
Figure 1.12: General overview of DNA shuffling
Zhao and Arnold, in 1997, came up with various modifications for DNA shuffling 
that focused on controlling the number o f mutations introduced in the shuffling process. 
The rate of mutagenesis was controlled by manipulating the concentration of DNA
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74- 7+polymerase, Mg and Mn in the PCR reactions. This approach was thought to have a 
higher impact on the evolution o f proteins and understanding the evolutionary related 
genes [9].
1.4.2.2 Targeted Evolution - Site-Directed Mutagenesis. The main goal of site 
directed mutagenesis is to introduce a single mutation at a particular site in the gene using 
mutagenic primers under regular PCR conditions. The goal is to obtain a single mutation, 
either a point mutation, deletion or insertion, with a minimum number of PCR cycles. 
Mutagenesis using mismatched oligonucleotides is currently being used in research to 
construct mutants. Other methods include mutagenesis using single stranded vectors, 
mutagenesis using double stranded vectors and mutagenesis by total chemical synthesis, 
as shown in Figure 1.13 [35],
Site-specific m utations in tro ­
duced a t a p a r tic u la r  location in 
Gene pool th f  gene
PC R  cycles
l *  l
111 i
a
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Site-specific Mutagenesis PCR 
Figure 1.13: Diagrammatic representation of mutation introduced due to site 
directed mutagenesis.
The basic operations performed in the method with mutagenic oligonucleotides 
involves using primers that have the mutagenic site either on one or both primers. The 
primers should anneal at the 5' end of the mutagenic sites and should be able to amplify 
the whole plasmid. Regular PCR conditions are set to allow the primers to anneal at the
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required site with a minimum number of cycles. Once the PCR product is obtained, it is
treated with Dpnl to get rid of the parent strand and transformed through the E. coli.
Plasmids obtained are confirmed through sequencing for the desired mutation [36].
1.4.3 Enhancing the Efficiency of Evolved Cre and 
Flp Recombinase Variants
To enhance the efficiency of evolved Cre and Flp recombinase variants, the 
recombinase can be fused to DNA binding domains of the Zinc-finger (ZF) module and 
TALE (transcription activator-like effector) module. These modules were designed to 
have specificity in binding to the DNA because o f their DNA binding domain. Similarly, 
CRISPR protein is another tool used in genome engineering for expanding the targeting 
efficiency o f the recombinases.
The ZFR (Zinc Finger Recombinases) perform the recombination autonomously 
and do not activate the DNA response pathway [18]. But the short-comings in using zinc- 
finger proteins are that they are limited only to the 64 possible triplet codon combinations 
[37], Furthermore, constructing zinc-finger proteins specific to certain DNA sequences is 
time consuming and labor intensive [42]. They perform integration with low specificity 
and can bind to off-target sequences and thus increase the risk of having higher rates of 
failure [38]. Due to these drawbacks, ZFR was replaced by more accurate technology like 
TALE and CRISPR.
CRISPR was used as an immune defense against invading DNA from 
bacteriophage viruses in many diverse bacteria and archaea groups [39,40]. This is the 
most recent addition in genome modification and genome engineering, where Cas9 
activity is based on the RNA-guided DNA endonuclease [40-42]. CRISPRs are used as a 
defense mechanism in bacteria and archaea against exogenous DNA. They are a fusion of
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CRISPR RNA (crRNA) and CRISPR associated (Cas) protein that together direct the 
degradation o f double strand DNA [40]. The double stranded breaks in the DNA due to 
Cas9 protein activate the non-homologus end joining (NHEJ) or the homology- directed 
(HDR) DNA repair pathway [42,43].
The nuclease in the Zinc-finger Nucleases (ZFN) and TALE nucleases can be 
substituted with site-specific recombinase [43], keeping the DNA binding domain and its 
function as it is, such that the recombinase can bind to the target sequence, and the DNA 
binding domain can be designed to bind to the DNA sequences upstream and downstream 
of the target site. DNA binding domains fused with recombinase can help in enhancing 
the efficiency of the recombinase by enhancing the interaction with their respective target 
recombination sequence. Discussed below are, in detail, the TALE DNA binding 
domains used to manipulate the genomic DNA. My project focuses on the use and 
optimization of TALE DNA binding domain linked to Cre recombinase to recognize the 
LL-69058 DNA sequences upstream of the beta globin gene.
1.4.3.1 TALE DNA-binding Domain. Transcription activator like effector 
(TALE) proteins provide an alternative for zinc finger recombinases. Advantages of 
using TALE proteins over ZFRs include greater DNA binding specificity, ease of 
engineering TALE DNA binding domains, and low toxicity and high cleavage activity 
when combined with recombinase [18,19], TALEs are naturally occurring DNA-binding 
domains derived from the plant bacterial pathogen Xanthomonas spp. and Ralstonia 
solanacearum [18,20,21]. The TALE proteins were used to modulate gene transcription 
in host plants to facilitate bacterial colonization where the proteins are delivered to the 
nucleus and then to a specific promoter sequence to activate gene expression [35,37].
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Generally, the DNA binding domain consists of 33-35 amino acid repeat modules 
that can be rearranged to bind to a new target DNA sequence [33,35,36]. Each DNA base 
(A, C, T and G) is encoded by repeat-variable di-residues (RVD's) called NI, HD, NG 
and NN respectively. The 'NI' RVD codes for 'A' DNA base, 'HD' for 'C \ 'NG' for T  and 
'NN' for 'G' DNA base. In Figure 1.14 below, the di-residues can be used to engineer the 
TALE DNA binding domain for any given sequence [38,39], The TALE binding domain 
is similar to the ZF binding domains, but the specificity to bind to each nucleotide in the 
sequence in higher and it can be engineered to bind to any target sequence, makes the 
TALE's preferred over ZF's [47].
Individual TALE repeat domains
B A 1 c 1 6 T[LI ■ H
Assemble modules
tTTACTGCTGCTCCCGCT
Engineered TALE repeat array
Figure 1.14: Coding pattern for each nucleotide base and engineering TALE DNA 
binding domain for a particular DNA sequence with the di-residue repeats.
In my studies, TAL (TALE) plays an important role in binding upstream and 
downstream of the LL-69058 target sequence, allowing the recombinase to bind 
specifically to the recombination target sequence. The protein in the TAL's is
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recombinase, Flp or Cre, which acts as the catalytic domain, and the TAL module, which 
acts as the DNA binding domain. As shown in Figure 1.15, the TAL DNA binding 
domain was engineered to bind to the sequence upstream of the LL-69058 target 
sequence, making it feasible for the evolved Cre recombinase to identify and bind with 
higher efficiency to its respective target site. Similarly, TAL can be engineered for 
another DNA sequence, where recombination activity is to be performed, thus improving 
the probability of having site-specific recombination rather than random recombination in 
the genome with other partially similar target sequences.
Left TAL DNA
binding domain C rf
variant
genomic DNA
Lett TAL LL-69058 Right TAL HBB Gene
Target Site Target Site
Figure 1.15: TAL DNA-binding domain designed to recognized the left TAL target 
site present upstream of the LL-69058 target sequence in the human beta globin 
(HBB) gene. The evolved Cre variants are attached to the TAL DNA binding 
domain proteins via a linker region.
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1.5 Using Evolved Cre and Flp Recombinase to Recognize 
Genomic LL and FL Target Sequence
The human genome has native recombinase target-like sites about every 5kb [5]. 
These genomic target-like sequences (LL and FL) are not similar to the loxP and FRT 
sequences in certain locations (Figure 1.16), but they can be utilized for recombination 
reactions by introducing or deleting certain DNA bases from the recombinase gene. The 
modification of these recombinases can be achieved using evolution techniques like DNA 
shuffling, PCR mutagenesis and error prone PCR. The modified or evolved Cre and Flp 
recombinases can be used to test if they can recognize genomic LL and FL sequences.
The applications of using site-specific tyrosine recombinases to modify the human 
genome are very wide spread and are utilized in gene therapy, gene targeting, and curing 
certain diseases [49]. When the recombinases are fused with TAL DNA-binding domain 
it helps in further increasing the efficiency of recombinases to bind at desired target 
sequences. Initially, when recombinase enzymes were discovered, gene knock outs were 
performed in mice after flanking the gene o f interest with loxP target sequence. Using 
TAL-recombinase fusion will be a useful approach as it would act as a good gene therapy 
technique for eradication o f many diseases. My project focuses on the potential cure for 
genetic diseases. Native recombination target sequences, loxP-like (LL) and FRT-like 
(FL) sequences, as discussed above, are utilized to perform integration and replacement 
recombination events. I believe that by using TAL DNA-binding domain fused to 
tyrosine recombinase, the efficiency of recombinase will be enhanced and my goal of 
attempting to find a potential remedy for replacing the mutated beta-globin gene with a 
healthy gene cassette can be accomplished.
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Figure 1.16: Comparison of FRT and FL-IL10A target sequence for evolved Flp 
recombinase (A) and loxP and LL-69058 target sequence for evolved Cre 
recombinase (B). The green color in the FL-IL10A and LL-69058 target sequences 
indicate similar bases to FRT and loxP target sequences, while red color indicates 
differences in the bases compared to FRT and loxP target sequence.
CHAPTER 2
METHODS
2.1 Objective 1 - Testing FL-IL10A Integration Using Evolved
Flp Recombinase 
2.1.1 Cell Lines and Transfection
Human embryonic kidney HEK 293 cells (ATCC, CRL-1573) were used as model 
mammalian cells and native genomic platform cells. The cells were propagated in 
DMEM medium. Cell transfections were performed using Polyfect (Qiagen).
2.1.2 Vectors
The reporter vectors for the integration experiments were based on the pcTD vector 
that is described in Anderson et al [50], The platform reporter pCMV-ILlOA-DsRed-neo 
and the incoming reporter pIL10A-puro-2A-EGFP, which were used in the integration 
experiments in HEK 293 cells, were generated as follows. The DsRed-neoR cassette from 
pIRES2-DsRed-Express (Clontech) was PCR amplified and subcloned into pcTD 
downstream from the CMV promoter to obtain pCMV-ILlOA-DsRed-neo. FL-ILI0A 
upstream of the DsRed-neoR cassette was introduced during the amplification of the 
cassette. The puroR gene from pCAGGS-Flpe-puro (Addgene plasmid 20733) and the 
EGFP gene from pIRES2-EGFP (Clontech) were PCR-assembled into one gene through 
the connecting 2A peptide and cloned into pcTD downstream from the CMV promoter to 
obtain pCMV-IL10A-puro-2A-EGFP. FRT/FL-IL10A upstream of the puro-2A-EGFP
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gene was introduced during its amplification. The CMV promoter in this plasmid was 
then deleted to obtain pIL10A-puro-2A-EGFP.
For the experiments with the intact HEK 293 cells, the pCMV-IL10A-puro-2A- 
EGFP reporter was modified by cloning the PGK promoter from pDIRE25 (Addgene 
plasmid 26745) upstream of the promoterless hygroR gene. To express Flp variants in 
mammalian cells, the respective genes were subcloned into pOG44 (Invitrogen) in place 
of the Flp-F70L variant gene as described in Anderson et al [50] (Figure 2.1).
pOGlOO
PC'MY.
/  Flp variant'
Nhel BamHI
Figure 2.1: Expression vector pOG44. The Flp variant is cloned between Nhel and 
BamHI restriction sites.
2.1.3 Construction of Platform Reporter Cell Lines
HEK 293-IL10A-DsRed-neo cell line was constructed by transfecting HEK 293 cells 
with pCMV-ILlOA-DsRed-neo, propagating them in medium supplemented with 
neomycin (800 mg/1) and selecting for the red colonies. Several such colonies were 
expanded and tested for singly integrated platform reporter vector by Southern blotting; 
the positive colonies were used in the integration experiments.
2.1.4 Integration Experiments
The analysis of the integration of the reporters into the respective genomic platform 
reporters was performed in the same general way for all three reporter pairs. The 
integration reaction was done in 6-well plates. The incoming reporters (0.5 pg) were co­
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transfected into the respective platform reporter cells with the vectors that express Flp 
variants analyzed. Forty eight hours post transfection, 1/6 of the cells were transferred 
into 100 mm plates, the cells were allowed to become confluent, and the number o f the 
green colonies was counted. Several integration positive colonies from these plates were 
expanded and analyzed.
The analysis o f the integration of modified incoming reporter with the 
hygromycin gene was tested in the native genomic platform. The transfection was 
performed in a 24-well plate. Forty eight hours post transfection, 1/4 of the cells were 
transferred into a 6-well plate. The cells were allowed to settle in the plate for 24 hours 
and then the medium was changed to hygromycin containing medium (500 pg/ml). The 
hygromycin medium was changed every two days in ten consecutive days until colonies 
were formed. The green and non-colored colonies were counted and the positive green 
colonies were expanded and analyzed.
2.1.5 Southern Blotting
Approximately 15 pg of genomic DNA isolated from HEK 293 cells were digested 
by SacI overnight followed by incubation with RNase A at 37° C for 1 hr. The digested 
DNA was then heat treated at 65°C for 5 min followed by cooling on ice for 5 min. The 
DNA fragments were separated on 0.7% TAE agarose (molecular biology grade,
BioRad). The gel was then treated with the depurination solution (0.25M HC1) for 15 min 
followed by the alkaline denaturing solution (two times for 30 min). The DNA fragments 
isolated from the gel were transferred to the positively charged nylon membrane 
(Amersham Hybond-N+, GE Healthcare) in the neutral transfer buffer (20X SSC, G- 
Biosciences). The membrane was then baked at 80°C for 40 min followed by UV
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treatment (5,000 microjoules). Next, the membrane was pre-hybridized in the 
ULTRAhyb hybridization buffer (Ambion) at 55°C for 30 min and then hybridized with 
the biotinylated EGFP probe (~ 1 pg) at 55°C overnight. The DNA bands were visualized 
using the Phototope-Star Detection Kit (New England Biolabs) according to the 
manufacturer’s protocol.
2.1.6 Other Methods
Plasmid DNA was isolated using GeneJET Plasmid Miniprep Kit (Thermo). 
Amplification of the DNA fragments used for cloning was performed using Pfu-Ultra 
polymerase (Agilent Technologies). PCR analysis of the mammalian genomic DNA was 
performed using Taq polymerase (New England Biolabs). Genomic DNA from cultured 
mammalian cells was isolated using GeneJET Genomic DNA Purification Kit (Thermo). 
General genetic engineering experiments were performed as described in Sambrook and 
Russell [51].
2.2 Objective 2 - Evolution and Testing of Cre Recombinase to Recognize
LL-69058 Target Sequence 
2.2.1 Bacterial Experiments
The E.coli strain NEB 10-beta [araD139A(ara-leu)7697 fhuA lacX74 galK 
(<|)80A(lacZ)M15) mcrA galU recAl endAl nupG rpsL (StrR) A(mrr-hsdRMS-mcrBC)] 
from New England Biolabs was used in all bacterial experiments. The deletion assays in 
E. coli were performed essentially as described in Voziyanov et al [10].
2.2.2 Cell Lines and Transfection
Chinese Hamster Ovary (CHO-TD1) cells were used as model mammalian cells. 
The CHO-TD1 cell line was constructed as described by Anderson et al [50] and are
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derivatives from CHO Flp-In cells (Invitrogen). Human embryonic kidney HEK 293 
(ATCC, CRL-1573) cells were used as wild type mammalian cells. The CHO-TD1 and 
HEK 293 cells were propagated in F-12K and EMEM/DMEM medium (Cellgro) 
respectively. Cell transfections were performed using DNA-In (MTI globoSTEM).
2.2.3 Oligonucleotides - Site-directed Mutagenesis
Mutagenic primers were designed to introduce particular mutations in the iCre 
recombinase gene. The list of various primers used and their positions are listed in the 
Table 2.1. The entire plasmid unwinds and was amplified with the forward and reverse 
primers in the presence of high fidelity polymerase Pfu (Aligent). The linear PCR product 
was then run on 1.5% agarose gel and treated with Dpnl (New England Lab) ensuring 
degradation o f the parent plasmid. The PCR mixture was then transformed through the 
competent E.coli cells and the circular form of the plasmid was regained on plasmid 
isolation. The plasmids were sequenced to confirm the desired mutation.
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Table 2.1: Forward and reverse primer sequences for introducing various site- 
directed mutations in the Cre recombinase gene.
T argeted 
Site-directed 
mutation 
position for 
iCre
recombinase
Forward Primer Reverse Primer
M ethionine
24
5'-
G G A TG C C A C C TC TG A TG A A G T C A IG A  
AG
AA CCTG ATG G ACATG TTCAG G -3'
5'-
CCTGAACATGTCCATCAG GTTCTTCA
T
G ACTTCATCAGAGG TG G CATCC-3'
V aline 24 5’-
GGATGCCACCTCTGATGAAGTCGIGAA  
G
AACCTGATGGACATGTTCAGG-3'
5'-
CCT G A AC ATGTCC ATC AGGTTCTTC AC 
G
ACTTCATCAGAGGTGGCATCC-3'
M ethionine 32 5'G AAG AACCTG  ATG G ACATGTTCAT
G G A CAG G CAG G CCTTCTCTG AACAC-
3’
5'-
GTGTTC AGAG AAGG CCTGCCTG TCCA  
TG AACATG TCCATCAG G TTCTTC-3'
4044 5'GACAG G CAG G CCTTCTCTG AANNN
ACCTG GAAG NNNCTCCTGTCTG TGTG
C A G A TC C TG -3’
5'-
C A G G A TC TG C A C A C A G A C A G G A G N N
NCT
TC C AG G TN NNTTC AG AG AAG G CCT G
CCTGTC-3'
24143 5'-
CCCCAACAACTACCTG TTCTG CCGG G  
TC AGA
AA G A ATG G TG TG G C TG CCC C-3’
5’-
G GG G CAG CCACACCATTCTTTCTGAC
CC
G G CAG AAC AG G TA G TTG TTG G G G -3’
6972 5’-G GAAATG G TTCCCTGCTG AACCT  
NNN GATGTG NNN  
GACTACCTCCTGT A C CTG -3’
5'-
C A G G TA C A G G A G G TA G TC N N N C A C A
TC
NNNAG CiTTCAGCAG GG AACCATTTC
C-3'
262 5’-CCCAACTG TCCACCCGG G CCCTG  
N N N  GGGATCTTTG AG GCCACCCACC- 
3’
5’-
G G TG G G TG G CCTCAAAG ATCCCNNN
CA
G GG CCCG GG TG GACAG TTG G G-3’
A l ( 25. 29, 32. 
33, 35)
5’-
G ATG AAG TCA G G AG G AAC CTG ATG A
GGA
TG TTCG AACTCAG G AG G GCCTTCTCT
G A A C A C -3’
5'-
G TGTTCAG AG AAG G CCCTCCTGAGTT
CGA
ACATCCTCATCAG GTTCCTCCTG ACT
TCATC-3'
A2 (337  ) 5'-
G GACTCTG AG ACTGG G GCCATGG TG
GAG
CTG CTCGAGG ATG G GG AC-3'
5'-
G TCCCCATCCTCG AG CAGCTCCACCA
TGG
CCCCAGTCTCAG AG TCC-3'
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2.2.4 PCR Mutagenesis (Error prone PCR) 
and DNA Shuffling
PCR mutagenesis o f the wild-type recombinase genes and DNA shuffling of the 
variant recombinase genes were performed as described in Bolusani et al [52]. In brief, 
mutagenic PCR was performed using Taq polymerase in the Mg-free buffer 
supplemented with 0.25 mM MnC12, 0.5 mM MgC12, 200 pM dNTP, 100 nM of each 
primer, and -100 ng of DNA template. After amplification, the PCR product was 
digested with SacI and SphI (iCre recombinase variant gene libraries) and was ligated to 
pBAD33 [52] digested with the respective enzymes. To perform DNA shuffling, genes of 
interest were amplified using Taq polymerase under non-mutagenic conditions. The PCR 
products were mixed in an equimolar ratio and fragmented with DNase I for 5 min on ice 
in the buffer containing 50 mM Tris-HCl (pH 7.4) and 10 mM MnC12. The resultant 
DNA fragments were reassembled in the two-step PCR reaction: first, using Pfu-Ultra 
polymerase without the addition of specific primers and then using Taq polymerase with 
specific primers that anneal outside the coding region of the genes. The TAL-Flp libraries 
were constructed by my lab colleague, and I tested the functionality o f the Flp libraries 
for the FL-71362 target sequence in the bacterial and mammalian cells.
2.2.5 Bacterial Screening Assay
The libraries obtained from site-directed or PCR mutagenesis and DNA shuffling 
were required to be screened through the bacterial system to detect potential activity by 
the recombinases. The Flp and Cre libraries were cloned in the pBAD33 expression 
vector between SacI and SphI restriction sites. These libraries were tested against a 
reporter vector p24 which consists of the hybrid FRT/FL-71362 and loxP/LL-69058 sites 
flanking the LacZ gene (Figure 2.2).
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Figure 2.2: Expression p33 and reporter p24 plasmids for bacterial screening assay.
Active libraries recognize the sites and bind to the target site in p24 resulting in 
the excision of the LacZ gene. Both the expression and the reporter vectors were 
transformed in the E.coli bacterial strain. These strains were initially made competent 
using the p24 reporter plasmid and then used to transform the expression plasmid for 
monitoring activity and screening.
2.2.6 Vectors
The reporter vectors for the replacement experiments were based on the pcTD vector 
that is described in Anderson et al [50]. The platform reporter p i372 (EFla-LL-69058- 
neo-STOP-FL-71362-DsRed) and the incoming reporter p i345 (691oxP/LL-EGFP-CMV- 
71FRT/FL), were used in the replacement experiments in CHO TD-In cells. The platform 
p i372 reporter was created by lab colleague. The incoming pi 345 reporter was generated 
by subcloning the EGFP gene from pIRES2-EGFP (Clontech) downstream of loxP/LL- 
69058 sequence followed by CMV promoter upstream of FRT/FL-71362 sequence, into 
pcTD.
The platform pi 372 reporter and the incoming pi 345 reporter, which were used 
in the replacement experiments in CHO TD-In cells, were constructed by modifying the 
respective reporters that were used to analyze the dual RMCE reaction by the Flp/Cre 
recombinase pair. For this, the neoR-STOP cassette of the platform reporter was flanked
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by the LL-69058 - FL-71362 sequence while the EGFP-CMV cassette o f the incoming 
reporter was flanked by the loxP/LL-69058 - FRT/FL-71362 sequence.
For the experiments in the intact HEK 293 cells, the p979 (691oxP/LL-CMV- 
EGFP -71FRT/FL-EFla-puro-2A-DsRed) incoming reporter was modified by cloning 
the inverted PGK promoter from pDIRE (Addgene plasmid 26745) upstream of the 
promoterless hygroR and ployA (from p6350) gene.
2.2.7 Construction of Platform Reporter CHO Cell Line
To construct the CHO TD-( EFla-LL-69058-neo-STOP-FL-71362-DsRed ) cell 
line, CHO TD-In cells were co-transfected, in 6-well plates, with the pl372(EFla-LL- 
69058-neo-STOP-FL-71362-DsRed) reporter (0.2 pg) and the pOG-TDl-40 vector (2 
jig), which express the TD1-40 variant o f TD recombinase. Forty eight hours post­
transfection, 1/6 of the cells were transferred into a 100 mm plate containing F12-K 
medium supplemented with hygromycin (550 mg/1). About 10 days later, several 
hygromycin resistant, colorless colonies were transferred into a 96-well plate and their 
sensitivity to zeocin was tested; zeocin sensitive colonies were expanded and used in the 
replacement experiments.
2.2.8 Construction of TAL Recombinases
2.2.8.1 Golden Gate TAL Construction. The DNA-binding domain o f TAL is 
built by the assembly of RVD's for a particular sequence. The sequence upstream and 
downstream of the LL-69058 target sequence was used as the DNA-binding domain for 
constructing left and right TAL respectively. The protocol for constructing the DNA- 
binding domain involves the following steps illustrated in Figure 2.3 and 2.4.
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>direct sequence
AGAGAA AGC ATTTA AGAGA AT A A AGC AAT GG AAAT AAG AA ATTTGT AAAT
t t c c t t c t g a t a a c t a g a a a t a g a g g a t c c a g t t t c t t t t g g t t a a c  c t a
AATTTT ATTTC ATTTT ATTGTTTT ATTTT ATTTT ATTTTATTTT ATTTTGT GTA 
ATCGTAGTTTCAGAGTGT 
>inverse sequence
ACTGGATCCTCTATTTCI AGTTATCAGAAGGAAATTTAC AAA I I 1 
O TATTTCC ATTGCTTT ATTCTCTT AAAT GCTTTCTCT ATT ATTGCT AAAT A 
AATAGAGATCTCTCACTTTTTCTACCTGTCTCAACCCTCATCAGGTACTTG
Figure 2.3: The direct and inverse sequences of the human beta-globin gene near the 
LL-69058. The target sequence is shown in green. The DNA binding domain for 
TAL downstream direct sequence (right TAL) and upstream inverse sequence (left 
TAL) are shown in blue.
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RVD Assembly For Right TAL DNA-binding Domain
A. TAL DNA-binding domain (Right) - 15 nucleotide sequence 
(.CTTAAC ( TAAAT I T
(; (; T I A A ( ( I A A A I T 1
NN NN NG NG NI NI HD HD NG NI NI NI NG NG NG
1 2 3 4 5 6 7 8 9 10 1 2 3 4 LR
j
pFUSA vector
B. TAL DNA-binding domain (Left) -15 nucleotide sequence
Y
pFUSB4 vector
AC A A A T T T C T T A T T T
A C A A A T 1 T C T T A I I T
NI HD NI NI NI NG NG NG HD NG NG NI NG NG NG
1 2 3 4 5 6 7 8 9 10 1 2 3 4 LR
V  J  \___________ )^ ---------------------------------------  y
pFUSA vector pFUSB4 vector
Figure 2.4 The construction of TAL DNA binding domain using single RVD's to 
clone into pFUSA and pFUSB vectors for the sequence located (downstream) right 
(A) and (upstream) left (B) of the LL-69058 target sequence.
A sequence consisting o f 18,15 and 12 nucleotides located upstream and 
downstream of the LL-69058 target sequence was selected to construct the TAL 
DNA-binding domain. Figures 2.3 and 2.4 indicate the upstream and downstream
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selected sequence and the construction of the binding domain for 15 nucleotides with 
single RVD's.
I. The first step was to assemble 10 nucleotides of the sequence with their 
respective RVD's (Figure 2.4). The assembly o f first ten RVD had to be cloned in the 
pFUSA vectors. The remaining nucleotides, 11-14, were assembled and cloned in another 
vector called pFUSB4. The last residue (LR) o f the sequence was kept as a single RVD 
and was not used in the first round of assembly. A 20pl PCR mixture consisting of 
pFUSA vector backbone, the first 10 nucleotide RVD, ligase, Bsal, ligase buffer, DTP 
and the remaining volume made up with water was prepared. A second 20 pi PCR 
mixture consisting o f pFUSB4 vector backbone, remaining 4 nucleotide RVD's, ligase, 
Bsal, ligase buffer, DTP and the remaining volume made up with water was prepared.
The PCR mix was incubated in a PCR machine for 20 cycles at 37°C for 15 minutes, 16°C 
for 10 minutes and then incubated at 50°C - 15 minutes and 16°C - 15 minutes and then 
heated again at 80°C - 20 minutes. After PCR, the mixture was passed through E.coli via 
transformation and plated on spectinomycin X-gal media plates. The pFUS vectors 
consist of LacZ appear blue if  the RVD's do not assemble in them, otherwise on RVD 
assembly the colonies appear white.
II. The white colonies were picked, the plasmid was isolated and sequenced so as 
to use the correctly assembled RVD's in pFUSA and pFUSB4 to further clone into the 
final pOG-TALE core vectors.
III. The pFUSA, pFUSB4 plasmid and the last residue (LR) were then assembled 
in the pOG-TAL core. The TAL core was amplified from the pTAL3 vector using 
different N and C terminal primers. The N terminal primers were designed to bind at the
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28, 63 and 75 nucleotide position and the C terminal primers are designed to bind at the 
117, 131 and 152 position in the pTAL3 plasmid.
The PCR mixture for final assembly consisted of pOG-TALE core vector, 
pFUSA, pFUSB4 vector, last repeat (LR), ligase, Esp3I, ligase buffer, DTP and the 
remaining volume made up with water. The PCR mixture was incubated for 20 cycles at 
37°C - 5 minutes and 16°C -10  minutes and then heated to 37°C -15 minutes, 16°C 
minutes and heated again at 80°C - 15 minutes. After PCR, the mixture was passed 
through E.coli via transformation and plated on Ampicilin X-gal plates. The pOG-TAL 
core has LacZ gene and if the pFUS vectors and last repeat were inserted in the 
pOG-TAL core, the colonies appeared white in color.
IV. The white colonies were picked and the plasmids were isolated. The plasmids 
were sent for sequencing and the correct plasmids were ready for being used to attach the 
Cre recombinase gene.
V. The Cre recombinase was amplified from the various variants mentioned in the 
tables above using Cre specific primers with additional sequence at the N terminal. The 
additional sequence is called the linker region which gives flexibility to the recombinase 
in order to find LL-69058 target sequence. The PCR product was digested with respective 
enzymes and cloned in the correctly assembled pOG-TAL core vectors.
2.2.8.2 Optimization of Linker Region Between the
TAL Domain and Recombinase. The linker region that connects the
TAL binding domain and recombinase were adjusted using different lengths o f linkers
called half, one and full (one and half) spacer sequence. The sequence of the linker
regions are listed in Table 2.2. The linkers were added to the iCre variant using primers.
The iCre gene along with different linker lengths were cloned in pOG vector between
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Nhel and BsrGI restriction sites and in pBAD33 vector between SacI and SphI restriction 
sites.
Table 2.2: Linker region sequences for half, one and half and full length. The 
underlined sequence indicate the common linker on which the one and half and full 
linker are built (Bold).
Half linker S'-GTCCCCATCCTCGAGCAGCCTCACC-S’
One linker 5^GCCGCTTCCGCCTGAGCCGTCCCCAfcCTCGAGCAGCCTCACC-
3'
Full linker 5'TGATGTGCCTGAGCCGCCGCTTCCGCCTGATCCTCCGCTTCC
G TCCCCATCCTCGAGCAGCCTC ACC-31
2.2.9 Dual Recombinase-Mediated Cassette Exchange 
(RMCE) Experiment in CHO Model Cells
The cassette exchange reaction between the incoming reporter pi 345 (691oxP/LL-
EGFP-CMV-71FRT/FL) and the platform reporter p i372 (EFla-LL-69058-neo-STOP-
FL-71362-DsRed) ( integrated into CHO TD-In) was performed similar to the integration
experiments. The incoming reporter (0.36 pg) and the expression vectors pOG-TAL-Cre
(0.003 pg) and pOG-TAL-Flp (0.02 pg) were co-transfected into CHO TD-l(EFla-LL-
69058-neo-STOP-FL-71362-DsRed) model cell line. Forty eight hours post transfection,
1/16 of the cells were transferred into 6-well plates, the cells were allowed to become
confluent, and the number of the green, red, and green/red colonies was counted. Several
green/red colonies from these plates were expanded and analyzed.
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2.2.10 Optimization of Right and Left pOG-TAL-recombinases 
for Efficient Binding in CHO Model Cells
The pOG-TAL-Cre variants were paired based on different lengths o f the TALE 
binding domain. Various concentrations of the left pOG-TAL-Cre recombinase were 
paired with the right pOG-TAL-Cre recombinase to analyze maximum attainment of 
green/red colonies in the CHO model cells.
2.2.11 Integration of pQG-TAL-Fln and pQG-TAL-Cre 
in Wild Type HEK 293
The analysis of the integration of the incoming reporters 979 (691oxP/LL-CMV- 
EGFP-inv PGK-hygro-pA-71FRT/FL-EFla-DsRed) into the respective genomic 
platform reporters was performed in the same general way for all three reporter pairs 
(Left/right TALE recombinases and incoming 979 reporter). The integration reaction was 
done in 24-well plates. The incoming reporters (0.45 pg) were co-transfected into the 
genomic platform with the vectors that express pOG-TAL-Flp (0.2 pg) variants (0.02 pg 
in the replacement experiments in CHO model cells) and pOG-TAL-Cre (0.3 pg) (0.003 
pg in the replacement experiment in CHO model cells) in separate wells. Forty eight 
hours post transfection, 1/4 of the cells were transferred into 6-well plates, the cells were 
allowed to settle in the well for 24 hours and then the medium was changed to 
hygromycin (500 pg/ml). The hygromycin medium was changed every 2 days for 10 
consecutive days until colonies were formed. The number of the green, red, green/red and 
non colored colonies was counted. Several integration positive colonies for pOG-TAL- 
Flp (just red not green) and pOG-TAL-Cre (just green not red) from these plates were 
expanded and analyzed.
CHAPTER 3
RESULTS
3.1 Results for Objective 1: Testing FL-IL10A Integration 
Using Evolved Flp Recombinasel531
3.1.1 FV7 is Active in Human Cells
Having established that FV7 is active in the integration and replacement reactions in 
CHO cells, we next tested the ability of FV7 to utilize the FL-IL10A sequence as a 
substrate in human cells in a model setting. For this, we integrated an FL-IL10A bearing 
platform reporter into human embryonic kidney 293 cells, HEK 293. In the integrated 
platform reporter, FL-IL10A is located between the CMV promoter and the DsRed gene 
(Figure 3.1 A). In the incoming reporter, the hybrid FRT/FL-IL10A sequence is located 
upstream of the promoterless puro-2A-EGFP gene. Upon integration o f the incoming 
reporter into the platform reporter, the expression of the puro-2A-EGFP gene is activated 
so the cells become green and resistant to puromycin.
To test what fraction of the green colonies represent the correct integration of the 
incoming reporter into the platform reporter, we subjected ten green colonies to PCR and 
Southern blot analyses. All ten colonies were positive for the integration specific PCR 
bands, (Figure 3 .ID), the identity of which was confirmed by sequencing. The Southern 
blot analysis showed that in all but one colony the incoming reporter was singly 
integrated into the platform reporter (Figure 3.1).
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Figure 3.1: Flp variants FV7, FV9 and their derivatives can integrate a reporter into 
the FL-IL10A site pre-integrated into the human genome. (A) Schematic outline of 
the integration assay. The horizontal blue and red bars in panels (A) and (D) 
schematically represent the PCR products at the left junction (LJ) and the right 
junction (RJ) of the integration product and the control PCR product of the 
platform reporter (C2). (B) Expanded green, puromycin-resistant cells do not 
express DsRed. (C) Southern blot analysis of the expanded green, puromycin- 
resistant colonies. The green bar in panels (A) and (C) shows the location of the
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integration-specific DNA fragment. M, biotinylated DNA marker. (D) PCR analyses 
of a typical green, puromycin-resistant colony. LJ and C l, the PCR analysis of the 
green cells and the control platform cells using the primers that anneal on the CMV 
promoter and the puroR gene. RJ and C2, the PCR analysis of the green cells and 
the control platform cells using the primers that anneal on the vector backbone and 
the DsRed gene. M, DNA marker. (E) The integration activity of the Flp variants 
FV7, FV9, FV7o, and FV9o as a function of the location of the NLS sequence and 
the input of the corresponding recombinase expression vectors at transfection. The 
results are represented by the data points connected by a line of the respective color. 
The data points show the mean value of five experiments; the error bars indicate 
standard deviation.
3.1.2 The Activity of FV7 in Human Cells can be Enhanced 
bv ‘Humanizing’ the FV7 Gene and bv 
Adding NLS to its Termini
The activity o f FV7 in human cells was low, so we explored two approaches to
increase it: (1) codon optimization o f the FV7 gene to maximize its expression in human
cells; and (2) addition of the SV40 nuclear localization sequence, NLS, to its N- or C-
termini to facilitate the crossing of FV7 into the nucleus. These modifications were
successfully applied to increase the activity of Cre and Flp in mammalian cells [54,55] In
the optimization experiments, in addition to FV7, we used a de novo evolved Flp variant,
FV9, which recombines FL-ILIOA in the bacterial deletion assay slightly better than FV7.
FV9 differs from FV7 at position 166: FV9 has wild-type Lys at this position while FV7
has Glu.
We tested the integration activity of the original and the modified recombinases at 
the different inputs o f the respective expression plasmids. FV7 was able to generate green 
cells only at the higher inputs: 4 pg and 0.4 pg of the expression plasmids per 
transfection (Fig. 3.IE, top panel). FV9 was more active than FV7 but it was not able to 
generate green cells at the lowest input of the expression plasmids tested: 0.013 pg 
(Figure 3 .IE, top panel). The ‘humanized’ versions of FV7 and FV9 -  FV7o and FV9o -
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had higher integration activity than FV7 and FV9 and were able to generate green cells 
even at the lowest input of the expression plasmids (Figure 3. IE, bottom panel). Unlike 
FV7 and FV9 that had essentially flat activity at the higher inputs o f the expression 
plasmids (4 pg and 0.4 pg), FV7o and FV9o had a pronounced peak of activity at 0.4 pg.
Although the addition o f NLS to the N- or C-termini of both non-optimized and 
optimized recombinase variants increased their integration activity, this modification was 
not powerful enough to allow the not-optimized FV7 and FV9 to generate green cells at 
the lowest input of the expression plasmids (Figure 3. IE, top panel). The variants with 
added NLS followed the FV7o and FV9o pattern and had a pronounced peak o f activity 
at 0.4 pg of the respective expression plasmids added at transfection (Figure 3. IE). For 
FV7 and FV9, it was the N-terminally placed NLS that helped them to achieve their 
highest integration activity. In contrast, the ‘humanized’ FV7o and FV9o benefited more 
from the C-terminal NLS. It was FV9o with this modification, FV9o-NLS, which showed 
the highest integration activity of all recombinase variants tested: ~ 0.35% of the 
transfected cells (Figure 3 .IE).
3.1.3 FV9o-NLS Can Target FL-IL10A Located in its 
Native Chromosomal Environment.
Finally, we tested the ability o f FV9o-NLS to integrate a reporter into the native 
FL-IL10A sequence in the intact HEK293 cells (Figure 3.2). For this, we modified the 
targeting vector described in the previous section to include the constitutively expressed 
hygromycin B phosphotransferase gene under the control of the PGK promoter (Figure 
3.2A) to help enrich the cell population that bears the integrated targeting vector.
The integration experiments were performed by co-transfecting the targeting 
vector and the FV9o-NLS expression vector into HEK293 cells. In the control
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experiments performed in parallel, the HEK293 cells were co-transfected with the 
targeting vector and the empty expression vector. Forty-eight hours post transfection, the 
cells were expanded in the hygromycin supplemented medium for about a week and the 
ratio of the green to non-green colonies assessed. Then, the cells were collected and 
analyzed by PCR and sequencing.
In the control experiments with the empty expression vector, the ratio o f the green 
to non-green colonies was 2.08±0.16. In contrast, the ratio o f the green to non-green 
colonies in the experiments with FV9o-NLS was significantly lower: 0.62±0.23 (Figure 
3.2B). The PCR analyses of the genomic DNA isolated from the collected cells showed 
that the characteristic, integration-specific bands were generated only when the cells were 
transfected with the FV9o-NLS expression vector but not with the empty one (Figure 
3.2C). Sequencing of the integration-specific bands confirmed the targeting of the 
FL-IL10A sequence (Figure 3.2C).
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Figure 3.2: FV9o-NLS can integrate a reporter into the native FL-IL10A sequence 
in the human genome. (A) Schematics of the integration assay. Upon expression of 
the FV9o-NLS variant, the incoming reporter can integrate into the native FL- 
IL10A site. Successful integration leads to the loss of the expression of the puro-2A- 
EGFP gene due to the separation from the promoter. (B) Co-transfection of the 
reporter and either the empty expression vector or the vector that expresses FV9o- 
NLS leads to the different ratios of green to non-green colonies. The results show the
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mean value of three experiments ± standard deviation. (C) The PCR and sequencing 
analyses of the pooled transfected and expanded cells. The analyses were performed 
at the left junction (LJ) and the right junction (RJ) of the integrated reporter vector 
and the genomic DNA. The blue and green bars in panels (A) and (C) show the 
location of the integration specific PCR products. Int, PCR analysis of the pooled 
transfected cells; Ctr, control PCR analysis of the original cells using the same 
primers as in lane ‘Int’; M, DNA marker. The FL-IL10A specific snapshots of the 
sequencing reads of the integration-positive PCR bands are shown on the right side 
of panel (C).
The overall goal of the above experiments was to test if the FV7 variant could 
recognize and integrate gene cassette in the HEK293 cells. FV7 is active in the 
mammalian cells. Its activity was enhanced when it was fused to C-terminal NLS 
sequence. Also when FV7 was codon optimized and fused to C-terminal NLS there was 
35-fold increase in integration activity.
3.2 Results for Objective 2; Evolution and Testing of Cre Recombinase to 
Recognize LL-69058 Target Sequence
3.2.1 TAL-Cre Variant is Active in the Bacterial 
Deletion System
My first experimental aim was to screen the evolved TAL-Cre variants to monitor 
efficient recombination activity at the LL-69058 target sequences in the bacterial deletion 
assay system. Evolved TAL-Cre variants (containing M24, V24, M32 mutations in Cre 
gene), Table 3.1 were passed via transformation through p24 reporter containing 
competent E.coli cells. The LacZ gene in the p24 reporter was flanked on either side with 
either LL-69058, loxP or hybrid LL-69058/loxP target sequences. The TAL-Cre variants 
were cloned in bacterial pBAD33expression vector. This expression vector containing a 
pBAD promoter and Arabinose operon have characteristic control on repression, 
induction and expression of genes cloned into the pBAD vectors [56]. Thus the amount 
o f TAL-Cre gene expression was tightly regulated by the Arabinose operon. The more
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the Arabinose in the culture medium, the more active was the Arabinose operon, resulting 
in higher production of TAL-Cre protein.
The assembled TAL core DNA-binding domain used for fusing the Cre variants 
was amplified from the pTAL3 vector. Each left and right arm of the TAL DNA-binding 
domain was assembled with RVD's for 18 nucleotides. The primers amplified the binding 
core beginning from the 95th position at the N-terminal and from position 117, 131 and 
152 at the C-terminal o f the pTAL3 vector. Therefore, the Cre variant was cloned in three 
different assembled TAL core DNA-binding domains named TAL 117+95, TALE 
131+95 and TALE 152+95, respectively, for initial bacterial screening. The Cre variants 
were PCR amplified using half linker region primers in order to fuse the TAL core DNA- 
binding region and Cre variant.
The different TAL-Cre variants upon being expressed bind to the target sequences 
flanking the LacZ gene resulting in the deletion of the LacZ gene. If the variants can 
recognize the target sequence, the colonies on the plate lose their blue color and appear 
white. Also the p24 reporter on the gel appears to migrate at a lower level compared to 
the original reporter (Figure 3.3), indicating that the TAL-Cre variant is active in the 
bacterial system and it deleted the LacZ gene. Various concentrations of arabinose were 
used to monitor high deletion activity in the bacterial cells.
Figure 3.3: Bacterial screening assay showing an agar plate containing chromogenic 
substrate X-gal with white and blue colonies (A). Gel image of plasmids isolated 
from the white and blue colonies (B). The topmost bands is the pBAD33 expression 
plasmids. The lower band indicates the p24 reporter where if the LacZ is deleted the 
plasmid migrates lower than the p24 reporter plasmid. Control (Cont) shows 
presence of two plasmids, containing LacZ (upper band and deleted LacZ (lower 
band) in the p24 reporter.
The bacterial assay with three different p24 reporter systems indicated some 
activity at 0.001% and 0.1% arabinose concentrations (Table 3.1). Out o f the various 
TAL-Cre variants passed through the bacterial deletion assay, TAL-Cre variant with a 
mutation at position 24 position in the Cre gene showed the highest deletion activity. The 
mutation at position 24 causes a change of amino acid from Arginine to Methionine.
It was observed that the bacterial deletion activity was highest with the pBAD33- 
TAL-117+95-Half linker-Cre-M24 variant. The pBAD33-TAL-l 17+95-Half linker-Cre- 
M24 variant showed 0.75% deletion activity (21 white colonies in 2800 colonies) at 
0.01% arabinose on genomic LL-69058 target sequence as compared to 0.7% (20 
colonies in 2800 colonies) deletion activity at 0.01% arabinose on wild type loxP target
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sequence. Therefore, the pBAD33-TAL-l 17+95-Half linker-Cre-M24 variant could 
recognize the genomic target sequence as efficiently at it could recognize the wild type 
target sequence. The Cre variants fused to TAL 131+95 and 152+95 showed no deletion 
activity in the bacterial assay. In the control experiments, plain Cre-M24 variant (without 
fusion to TAL core DNA-binding domain) was passed through the bacterial screening 
assay to test the deletion efficiency. There was no deletion activity observed and the 
results were unsuccessful.
Table 3.1: The target sequences used in p24 reporter flanking the LacZ gene and the 
deletion activity observed under 0.001% and 0.01% of arabinose concentration. The 
red highlight indicates the only activity observed in the bacterial assay.
Target sequence in p24 reporter 
flanking the LacZ gene
Arabinose
concentration
Deletion activity in 
bacterial cells 
(2800 colonies/big plate)
Genomic LL-69058
TTTCCTTCTGATAA CTAGAA 
AT AGAGGATCCAGT
0.001% 0% white colonies
0.01% 0.75% white colonies, no 
semi-blue colonies.
loxP -loxP (Full)
AT AACTTCGT AT AG CTAGAA 
TTATACGAAGTTAT
0.001% Just 2 white colonies in 
2800 colonies, (negligible 
activity)
0.01% 0.7% w hite colonies, 
30% semi-blue colonies.
Genomic-loxP (Half)
TTTCCTTCTGATAA CTAGAA 
TTATACGAAGTTAT
0.001% 0% white colonies
0.01% Just 1 white colony in 
2800 colonies, 
(negligible activity)
Though the deletion activity with pBAD33-TAL-l 17+95-Half linker-Cre-M24 
was low in the bacterial system, it still showed significant activity to test the TAL-Cre 
variant in the mammalian cells. The active pBAD33-TAL-l 17+95-Half linkerCre-M24 
variant was then transferred into pOG expression vector to test the replacement activity in
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mammalian cells. Furthermore, in the next experiments, pOG-TAL-117+95-Half linker- 
Cre-M24 variant will be addressed as TAL-Cre-M24.
3.2.2 Selection O f Active Cre Variants Obtained
Through DNA Shuffling
As the TAL-Cre-M24 variant showed some activity in the bacterial assay, new 
Cre libraries were built keeping Cre-M24 as the base template. Table 3.2 below shows 
various random mutations introduced in the Cre-M24 gene during DNA-shuffling and 
error prone PCR protocols. The Cre libraries were directly cloned in the mammalian 
expression vectors to test the replacement efficiency in the model CHO cells. The Cre 
variants were also fused to the TALE-core DNA-binding domain to compare the activity 
between Cre variants with and without the TAL-core DNA-binding domain. The 
experiments with Cre variants not fused to the TAL-core-DNA-binding domain were 
unsuccessful and did not give any green/red colonies in the replacement experiments. But 
the Cre variants fused to TAL-core DNA-binding domain had few green/red colonies, but 
on expansion of these colonies the green color faded leaving just red colonies. These 
results are unexpected and thus the Cre variants cannot be used for the replacement 
experiments (Table 3.2).
Table 3.2: Random mutations introduced in Cre recombinase gene using error 
prone PCR or DNA shuffling methods.
Variant No. Amino Acid 
(AA)Change
AA
Position
No.
Protein Change Protein
Position
No.
iCreM24- l.G A A to  AAT 1.808 E to N (Glu to Asn) 262
262-1
iCreM24- l.G A A to  AAA 1.223 1. E to K (Glu to Lys) 67
262-14 2. GAC to AAC 2.241 2. D to N (Asp to Asn) 73
3. GAA to AGC 3. 880 3. E to S (Glu to Ser) 262
iCreM24- l.G A A to  AGC 1. 880 E to S ( Glu to Ser) 262
262-21
iCre ScSh 1. AGG to ATG 1.95 R to M (Arg to Met) 24
9-1 2. AAC to GAC 2. 199 N to D (Asp to Asp) 59
3. GAT to AAT 3. 589 D to N (Asp to Asn) 189
4. GTG to GCG 4. 650 V to A (Val to Ala) 209
5. GAA to GGA 5. 809 E to G (Glu to Gly) 262
iCre 6-2 Loss of two 
nucleotides-CT
1036 Loss of Leu codon 337
3.2.3 TAL-Cre M24 Can Perform Efficient Replacement 
of Gene Cassette in CHO Model Cells
To test if  a target-specific TAL-Cre-M24 variant can be combined with another 
site-specific recombinase to perform dual recombinase-mediated cassette exchange (dual 
RMCE) in mammalian cells, we paired TAL-Cre-M24 with TAL-Flp in a model setting 
similar to what we used to analyze the replacement activity of the Flp/HK022 Int 
recombinase pair [29], The TAL-Flp variant was constructed and evolved by another 
member of the lab and I tested and optimized the variant in replacement experiments. For 
this, the respective cognate target sequences were introduced for Cre and Flp in the
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incoming and platform reporters of the replacement system (Figure 3.4) and the platform 
reporter was then integrated into genome of CHO cells.
A schematic of the assay to test the replacement activity of the TAL-Cre- 
M24/TAL-Flp recombinase pair is shown in Figure 3.4(A). In the integrated platform 
reporter, LL-69058 target sequence is located between the E F la  promoter and the neoR 
gene while FL-71362 target sequence is located upstream of the promoterless DsRed 
gene. The incoming reporter bears the hybrid loxPILL-69058 site upstream of the 
promoterless EGFP gene whereas FL-71362/FRT is positioned downstream of the CMV 
promoter. If the TAL-CreM24/TAL-Flp recombinase pair is active in the dual RMCE 
reaction, the neoR-STOP cassette o f the platform reporter will be replaced with the 
EGFP-CMV cassette of the incoming reporter; this recombination event can be detected 
by the activation of the expression of both EGFP and DsRed genes in the same cell. The 
expression o f just DsRed will indicate the Flp-dependent integration o f the incoming 
reporter into the platform reporter at the FL-71362 site while the expression of just EGFP 
will signify the CreM24-dependent integration o f the incoming reporter into the platform 
reporter at the LL-69058 site.
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Figure 3.4: Dual recoinbinase-mediated cassette exchange, RMCE, mediated by 
TAL-Cre-M24 and TAL-Flp variants at relative location of the loxP-Iike sequence 
LL69 (LL-69058) and FRT-like sequence FL71 (FL-71362) in the CHO model 
genome. (A) Schematic of the dual RMCE reaction to test the replacement activity 
of the Cre and Flp variants. The cells, in which the replacement occurred, express 
both EGFP and DsRed on efficient replacement. (B) The green/red colony formed 
after the active TAL-Cre-M24 and TAL-Flp variants recognize and replace the gene 
cassette at the genomic target sequences in model cells. (C) The left and right 
junction PCR analysis bands confirm the replacement of gene cassette by the 
correct band size of 750bp at left junction and the band size of 700 bp at the right 
junction. (D) The sequencing of the PCR bands indicate the genomic LL-69058 
sequence at the left junction highlighted in green and the FL-71362 sequence at the 
right junction highlighted in red. The blue highlighted regions in the left junction 
sequence are the left and right TALE-core DNA-binding domains for TALE-Cre- 
M24 variant.
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To perform the replacement, we co-transfected the platform reporter cells with the 
incoming reporter and the vectors that express TAL-Cre-M24 and TAL-Flp. Forty eight 
hours post-transfection, the cells were expanded and examined for the colonies that 
express either EGFP or DsRed, or both (Figure 3.4A and B). These colonies and not 
individual cells that express EGFP and/or DsRed were considered true indicators of 
recombination events. To confirm that the EGFP and DsRed expression in the green/red 
colonies reflects the expected reporter replacement, we expanded several such cell groups 
and analyzed them by PCR (Figure 3.4C) and sequencing. Approximately 1 or 2 
green/red colonies were obtained after every transfection from 25 pi o f cells transferred 
in a 6-well plate.
3.2.4 Cre M32 Variant Shows High Recombination Activity 
when Fused with Left TAL (15 nucleotide).
Right TAL (12 nucleotide) and Half 
Spacer Region
As the number o f green/red colonies obtained in the replacement experiment was 
less with the TAL-Cre-M24/TAL-Flp variants, it was necessary to find an alternative 
approach to increase the yield o f green/red colonies. The TAL-core DNA-binding 
domains were first altered to observe if there was any significant change in the number of 
green/red colonies. In the above replacement experiment, the left and right assembled 
TAL DNA-binding domains were assembled with RVD's for 18 nucleotides. New TAL- 
core DNA-binding domains were constructed by assembling RVD's for 12 and 15 
nucleotides for both left and right arms. The Cre-M24 variant was cloned with a half 
linker region in the assembled TAL-core DNA-binding domain. Different combinations 
o f left and right arms were optimized by co-transfecting the plasmids in model CHO cells 
to observe the replacement efficiency.
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We observed a 5-fold increase in the replacement activity when the combination 
o f 12 nucleotide RVD (RV12) assembly and 15 nucleotide RVD (LV15) assembly were 
fused with Cre-M24 variant prior to transfection. On average at least five green/red 
colonies were observed with every 25 pi transfer of cells into 6-well plate. The 
transfections were performed by co-transfecting these new TAL RV12 and TAL LV15 
Cre-M24 variants with TAL-Flp and the incoming reporter. On expansion and PCR 
analysis, the PCR produce was of the correct size and the sequencing confirmed the 
replacement of the gene cassette.
To continue improving efficiency, the linker region fused to the TAL-core DNA- 
binding domain and Cre-M24 variant was altered. The number of green/red colonies 
observed with one and full linker spacer region between the TAL-core and recombinase 
was five times less compared to the original half linker region. This attempt o f altering 
the linker region was unsuccessful and the half linker proved to be the better fit for 
allowing the Cre variant to recognize the genomic LL-69058 target sequence. Our next 
aim was to alter the TAL-core length at the N-terminal. The original TAL-Cre-M24 
variant had the combination of 117+95. As 117 at the C-terminal was the only position 
that gave activity in the bacterial assay, no alterations were performed at the C-terminal. 
New TAL-core plasmids were built with +28 and +63 starting lengths at the N-terminal 
that were PCR amplified from the pTAL3 vector. The new TAL-core 117+28 and TAL- 
core 117+63 were assembled with right 12 nucleotide RVD's and left 15 nucleotide 
RVD's and later fused with Cre-M24 variant with a half spacer region.
The transfections with 117+95, 117+63 and 117+28 TAL-core left and right 
TAL-core DNA-binding domains fused to Cre-M24 variant were performed in the model
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CHO cells along with the incoming reporter and TAL-Flp variant. The replacement 
efficiency was calculated based on the number o f green/red colonies observed and it was 
noted that 117+95 TAL-core had two times more green/red colonies compared to 117+63 
and 117+28 TAL-cores.
Thus the best combination of TAL-core DNA-binding domain fused to Cre-M24
variant was the TALI 17+95-half spacer-Cre-M24 with left arm of 15 nucleotides (LV15
and right arm with 12 nucleotide (RV12). In control experiments, Cre-M24 was used in
the replacement experiments, to observe if the recombination efficiency without the TAL
domain attached. There was no significant activity when plain Cre-M24 variant was
added in the experiment. The new version o f TAL-Cre-M24 is addressed as TAL-Cre-
M24 -LV15/RV12. TAL plays a major role in guiding the Cre-M24 variant to recognize
and bind to the genomic target sequence.
3.2.5 Integration in HEK 293 Cells with 
TAL-Flp Active Variant
The next goal was to test the ability o f TAL-Flp variant to integrate 979 
(691oxP/LL-CMV-EGFP -71FRT/FL-EF1 a-puro-2A-DsRed) reporter into the native FL- 
71362 target sequence in the intact HEK293 cells (Figure 3.5). For this, we modified the 
979 reporter vector described in the previous section to include the constitutively 
expressed inverted hygromycin B resistant gene under the control o f the PGK promoter 
(Figure 3.5A) to help enrich the cell population containing the integrated vector.
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Figure 3.5: Hybrid TAL-Flp variant FV71 specific for the FRT-Iike sequence FL71 
located in the human beta-globin gene can be used to deliver a reporter vector into 
the gene in intact human cells. (A) Schematic of the integration reaction. (B) The 
characteristic PCR band is generated in the experimental but not in the control 
integration reactions. Sequencing of the positive PCR band confirmed its identity.
The integration experiments were performed by co-transfecting the 979 reporter 
vector and the TAL-Flp expression vector into HEK293 cells. In the control experiments 
performed in parallel, the HEK293 cells were co-transfected with the 979 reporter vector 
and the empty pOG expression vector. 48 hours post transfection, the cells were 
expanded in the hygromycin supplemented medium for about a week and the ratio o f the 
number o f green but not red colonies to other colonies (red and green, non colored, and 
red but not green) was assessed. Then, the cells were collected and analyzed by PCR and 
sequencing.
In the control experiments with the empty expression vector, the ratio of the green 
to other colonies was 0.87±1.62. In contrast, the ratio of the green to other colonies in the 
experiments with TAL-Flp was nearly similar: 0.95±0.23. The PCR analyses o f the 
genomic DNA isolated from the collected cells showed that the characteristic,
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integration-specific bands were generated only when the cells were transfected with the
TAL-Flp variant expression vector but not with the empty one. The sequencing results of
the integration-specific band confirmed the FL-71362 sequence obtained from the PCR
and also confirmed that site-specific integration had occurred.
3.2.6 Integration in HEK 293 Cells with Active 
TAL-Cre M24- LV15/RV12 Variant
The integration experiment with the TAL-Cre-M24-LV15/RV12 variant was
performed three times in the HEK293 cells and the data presented below is from one of
the experiments that gave the positive result. The TAL-Cre-M24- LV15/RV12 variant
ability to integrate 979 (691oxP/LL-CMV-EGFP -71FRT/FL-EF1 a-puro-2A-DsRed)
reporter into the native LL-69058 target sequence was tested in the intact HEK293 cells
(Figure 3.6). For this, the modified 979 reporter vector was used which is described in the
previous section. The modification was to include the constitutively expressed inverted
hygromycin B resistant gene under the control of the PGK promoter (Figure 3.6) to help
enrich the cell population containing the integrated vector.
loxP/LL-69
^  CV69
A A ►
beta-globin gene yy y y
LL-69
LJ: ~0.8kb
LL-69 loxP/LL-69
Figure 3.6: Hybrid TAL-Cre-M24 variant specific for the loxP-Iike sequence LL-69 
(abbreviation for LL-69058) located in the human beta-globin gene can be used to 
deliver a reporter vector into the gene in intact human cells.
The integration experiments were performed by co-transfecting the 979 reporter 
vector and the TAL-Cre-M24-LV15/RV12 expression vector into HEK293 cells. In the 
control experiments performed in parallel, the HEK293 cells were co-transfected with the 
979 reporter vector and the empty pOG expression vector. Forty eight hours post 
transfection, the cells were expanded in the hygromycin supplemented medium for about 
a week and the ratio o f the number o f red but not green colonies to other colonies (red 
and green, non-colored, and green but not red) was assessed. Then, the cells were 
collected and analyzed by PCR and sequencing.
In the control experiments with the empty expression vector, the ratio of the red to 
all other colonies was 0.142. In contrast, the ratio of the red to all other in the 
experiments with TAL-Cre-M24-LV15/RV12 was significantly lower: 0.087. The PCR
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analyses of the genomic DNA isolated from the collected cells showed that the 
characteristic, integration-specific bands were generated only when the cells were 
transfected with the TAL-Cre-M24 variant expression vector but not with the empty one. 
Sequencing of the integration-specific bands confirmed the targeting of the LL-69058 
target sequence.
The overall goal o f the above experiments was to perform replacement reaction in 
the model CHO and HEK293 mammalian cells with functional Cre variant that was able 
to recognize the genomic LL-69058 target sequence. Variant TAL-Cre-M24-RV12/LV15 
proved to be an active variant that could recognize the genomic site and efficiently 
replace and integrate gene cassette into the genome.
CHAPTER 4
DISCUSSION
The power o f the tyrosine site-specific recombinases to edit genomes is widely 
realized but only in the approaches that employ the pre-introduced cognate wild-type (or 
essentially wild-type) recombination targets. The approaches that would utilize genomic 
target-like sequences in their native chromosomal environment could add a valuable tool 
to the genome engineering toolbox but are yet to be developed. The work presented in 
this dissertation shows that the field can be advanced if genome manipulation methods 
are developed around target-specific recombinase variants that are evolved to be active in 
bacteria and further modified to optimize their expression level and their delivery into the 
nucleus in the cells of interest.
The performance o f FV7 in human HEK 293 cells did not mirror its performance in 
hamster CHO cells: the integration efficiency of FV7 in CHO cells was -0.1%  of the 
transfected cells whereas it was only -0.01 % in HEK 293 cells. To improve the 
integration activity of FV7 in human cells, we optimized the codons o f the FV7 gene to 
maximize its expression in human cells and/or added the nuclear localization sequence to 
the variant to enhance its ability to get into nucleus. The use of the de novo evolved Flp 
variant, FV9, which recombines FL-IL10A in E. coli slightly better than FV7, was also 
helpful in increasing the efficiency of FL-IL10A targeting.
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The effect of the codon optimization on the integration activity o f FV7 and FV9 was 
quite positive allowing the optimized variants, FV7o and FV9o, to have integration 
activity over almost three-fold higher versus one-fold higher for FV7 and two-fold higher 
for FV9 (Figure 3. IE). The activity increase was not uniform over the range of the 
expression plasmid inputs: the peaks o f the integration activity were detected at the 
moderate input of the recombinase expression vectors. The codon optimization effect was 
more pronounced for FV7: under optimal conditions, FV7o and FV9o were about 10 fold 
and 5 fold more active than FV7 and FV9, respectively (Figure 3.IE).
The addition of NLS to the original and to the codon-optimized recombinase variants 
increased their integration activity: FV7 and FV9 showed a higher relative increase than 
their ‘humanized’ versions while FV7o and FV9o showed higher absolute integration 
activity (Figure 3. IE). The integration activity o f the NLS modified recombinase 
variants, as well as the unmodified FV7o and FV9o, exhibited sharp dependence on the 
input of the respective recombinase expression vectors. The sharp peaks o f the 
integration activity that depend on the recombinase input are not unusual for the tyrosine 
recombinases and were noted before in the targeting experiments with the purified Cre 
recombinase [57]. Such sharp peaks may reflect a narrow window of the optimal 
combination o f the efficiency of the reversible integration-excision reactions and the 
input of a recombinase.
The original and the ‘humanized’ NLS-modified Flp variants had different activity 
patterns at the moderate input of the recombinase expression vectors (the one that permits 
the highest integration activity of the recombinase variants (Figure 3.1 E). At this input, 
FV7 and FV9 with N-terminal NLS showed higher integration activity than their C-
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terminal versions. In contrast, FV7o and FV9o variants showed the inverse activity 
pattern: the variants with C-terminal NLS were more active than their N-terminal 
counterparts (Figure 3. IE). Since the integration activity o f a recombinase in a cell was 
found to depend not only on the actual ability o f this enzyme to recombine a particular 
DNA sequence but also on the concentration of the recombinase [57] and the timing of its 
expression [58]. The observed differences in the activity o f the NLS-modified variants 
may be explained by the differences in the expression of the variants and the timing of 
their appearance in the nucleus. Indeed, the codon optimization and the addition of NLS 
can affect these parameters. Another factor to consider is a potential effect o f NLS and its 
location on the actual enzymatic activity of a recombinase variant.
Taken together, the codon optimization of a recombinase gene, the addition of NLS, 
and the use of a more active Flp variant resulted in an approximately 35-fold increase in 
the targeting efficiency o f FL-IL10A in human cells in the model setting: FV7 was able to 
integrate a reporter in -0.01%  of the transfected cells while the ‘humanized’ version of 
FV9 with C-terminally placed NLS performed the task in -0.35%  of the transfected cells.
In the model setting of human cells FV7 was capable o f targeting FL-IL10A 
accurately: out of ten randomly expanded integration-positive clones, only one clone had 
vector integrated somewhere else in the genome, in addition to the correctly integrated 
vector (Figure 3.1C).
Tyrosine recombinase variants that are specific for the genomic target-like sequences 
are useful only if they are able to utilize these sequences in their native chromosomal 
environment. Therefore, after improving the integration activity of the Flp variants in 
human cells in the model setting, we tested whether these variants can recombine the FL-
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IL10A sequence in its native chromosomal environment in the unmodified human cells. 
The successful targeting of FL-IL10A demonstrated that sequence specific Flp variants 
are indeed capable of accomplishing the task (Figure 3.2). To our knowledge, similar 
results for tyrosine recombinases have not been demonstrated before. Indeed, in the 
earlier report, a Cre variant evolved to recombine a loxP-like sequence in the LTRs of 
FIIV-1 was shown to target this sequence in the human cells [59], However, since a copy 
of the HIV-1 pseudotype genome used in that study was randomly integrated and stably 
maintained in the human cells, the resultant HIV-1 provirus should be considered a pre­
introduced model recombination reporter, functionally equivalent to any model 
recombination reporter for this matter. Therefore, although quite remarkable, the 
experiments described by Sarkar et al. [59] do not demonstrate that tyrosine 
recombinases variants are able to utilize genomic target-like sequences in their native 
chromosomal locale.
The performance of TAL-Cre-M24 against just plain Cre-M24 was tested in the 
bacterial, CHO model cells and HEK293 cells for efficient recombination activity.
Though the experimental attempts with plain Cre-M24 were unsuccessful in all the three 
screening systems, when Cre-M24 was fused to the TAL-core DNA-binding domain 
recombination sufficient activity was observed. The other Cre variants listed in Table 3.2 
had various mutations at the DNA-recombinase interaction points, and were also 
screened through the bacterial and CHO model cell systems. The random mutations in the 
Cre variants were such that it would loosen the complexity with which the Cre monomer- 
monomer interact or Cre-DNA interact leading to a flexible approach for them to 
recognize the target sequence. These variants were screened with and without attachment
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of TAL-core DNA-binding domain, but all attempts to achieve minimal recombination 
activity failed. There were a few green/red colonies observed with TAL-core DNA- 
binding domain variant, but the green color always faded in the colonies on expansion. I 
am not sure about any particular reason behind the fading of green color, but there can be 
silencing of the EGFP gene when the reporter and expression plasmids are present in the 
same cell either activating or suppressing certain pathways or there can be random 
integrations in the genome that cause the EGFP to lose its expression in the cells. TAL- 
Cre-M24 was the only active variant we attained from all the directed evolution protocols 
that showed 0.1% replacement activity in the CHO model cells.
The initial construction o f TAL-Cre-M24 consisted of 18 nucleotide RVD's 
assembled on left and right arms o f DNA-binding domains. Half spacer region was used 
to fuse the Cre and the TAL-core DNA-binding domains. There was a minimal 
recombination activity observed in the bacterial and CHO model cells. On an average just 
one green/red colony was observed every transfection reaction. Attempts were made to 
have better replacement activity in CHO model cells by modifying the TAL-core, the 
DNA-binding domains o f TAL-Cre-M24 variant and the linker region present between 
the Cre and TAL-core DNA-binding domain. Various combinations of the TAL core 
ranging from 117+95,117+63 and 117+28 C to N terminal were tested in the model cells. 
There was a two-fold difference in activity amongst the TAL-core with 117+95 TAL- 
core being highly efficient. Thus the decision we made of using TAL-core 117+95 in 
previous experiments was helpful. We also observed that half linker region proved to be a 
better match between the TAL-core DNA-binding region and Cre-M24 variant as it 
provided enough flexibility to Cre-M24 to recognize and bind at the genomic LL-69058
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target sequence. Half linker regions had two-fold better activity compared with one and 
full linker spacer regions.
Furthermore, out of the various DNA-binding domain arms, the combination o f 15 
and 12 RVD's on the left and right arm respectively, proved to be highly efficient when 
fused with Cre-M24 variant, increasing the recombination activity by five-fold in the 
model cells. Thus the new version: TALE-117+95-Half linker-Cre-M24, left LV15 and 
right RV12 combination was 5-fold more efficient than the old version: TAL-117+95- 
Half linker-Cre-M24, left LV18 and right RV18. The new version TAL-117+95-Half 
linker-Cre-M24 is referred to as TAL-Cre-M24-LV15/RV12 in all my experiments. 
Overall it was observed that the major increase in the recombination efficiency was 
basically due to the change in the DNA-binding domain arms. As the arms were 
shortened to 15 and 12 nucleotides, they tended to improve by the replacement efficiency 
by 0.58%. The mutation at the 24th position in the Cre gene helped in releasing the tight 
bonding between the monomer-monomer protein subunits and when the Cre-M24 variant 
is cloned with the shorter arms of TAL-domans, it becomes feasible for the recombinase 
to bind at the LL-69058 target sequence. As the arms are short and closer to the target 
sequence (Figure 3.4 D) they bind firmly to the DNA giving full access and flexibility to 
the Cre recombinase with half linker region. As we have seen in control experiments, 
plain Cre-M24 just did not show any recombination activity. Thus only when Cre-M24 is 
bonded to TAL-domain does it serve our purpose.
In the next experiments we tested the TAL-Cre-M24-LV15/RV12 variant in the 
native genomic environment. As the experiment was performed just once, the data 
represented here is from one time PCR analysis and sequencing. The TAL-Cre-M24
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variant successfully integrated at the genomic LL-69058 target sequence (Figure 3.6).
The results were confirmed through sequencing of the correct size (-800 bp) PCR band. 
More TAL-Cre-M24 based integration experiments in the HEK293 cells are to be 
performed in the future to confirm the results. TAL-Flp variant was also tested for its 
recombination efficiency in the native genomic environment in the FIEK293 cells.
Several integration experiments were performed and it was observed that TAL-Flp 
variant recognizes the genomic FL-71362 as confirmed by PCR band size and 
sequencing. Therefore, both the evolved TAL-Cre-M24 and TAL-Flp recombinases can 
recognize the genomic target sequences separately when tested in the human cells.
Future experiments aim at using both the evolved TAL-Cre-M24 and TAL-Flp 
recombinases simultaneously by co-transfecting them along with the reporter plasmid to 
recognize the genomic LL-69058 and FL-71362 target sequences and perform successful 
replacement of the gene cassette in the native genomic environment. Various 
concentrations o f the recombinases are to be tested and optimized to have consistent 
replacement. If the dual RMCE attempt is successful in the genomic environment then we 
can prove to have a potential cure for the sickle cell disease. As the genomic target 
sequences LL-69058 and FL-71362 flank the beta-globin gene that consists the mutation 
causing sickle cell disease, replacing the gene cassette between the two target sequences 
would replace the mutated region with a normal gene region. It could be used as gene 
therapy for sickle cell disease. This fundamental approach o f evolving recombinases to 
recognize genomic target-like sequences, can also be applied to cure other diseases that 
tend to possess recombinase target-like sequences in their vicinity in the human genome.
APPENDIX
SUPPLEMENTAL FIGURES AND SEQUENCES
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Figure A .l: Sequencing results snapshot of the FV7-mediated integration product of 
the incoming reporter into FL-IL10A located in the platform reporter pre­
integrated into the HEK 293 genome (see Figure 3.1). (A) Schematic of the 
integration product. The horizontal green and red bars represent the diagnostic 
PCR products at the left junction (LJ) and the right junction (RJ) of the integration 
product. (B) The sequencing results snapshots of the respective PCR products are 
shown below the schematics of the resultant recombination sites and the 
surrounding sequences.
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Protein alignment of the whole sequences for iCreM32-iCre262-l, 14,21.
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ *  ★ ★ *
iCreM24
MVPKKKRKVSNLLTVHQNLPALPVDATSDEVMKNLMDMFRDRQAFSEHTWKMLLSVCRSW 60
iCre-262-1
MVPKKKRKVSNLLTVHQNLPALPVDATSDEVMKNLMDMFRDRQAFSEHTWKMLLSVCRSW 60
iCre-262-21
MVPKKKRKVSNLLTVHQNLPALPVDATSDEVMKNLMDMFRDRQAFSEHTWKMLLSVCRSW 60
iCre-262-14
MVPKKKRKVSNLLTVHQNLPALPVDATSDEVMKNLMDMFRDRQAFSEHTWKMLLSVCRSW 60
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ -k  -k  -k
iCreM24
AAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNA 120
iCre-2 62-1
AAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNA 120
iCre-262-21
AAWCKLNNRKWFPAEPEDVRDYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNA 120
iCre-262-14
AAWCKLNNRKWFPAKPEDVRNYLLYLQARGLAVKTIQQHLGQLNMLHRRSGLPRPSDSNA
★  ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★  • • ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
iCreM24
VSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLL 180
iCreM-262-1
VSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLL 180
iCreM-262-21
VSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLL 180
iCreM-262-14
VSLVMRRIRKENVDAGERAKQALAFERTDFDQVRSLMENSDRCQDIRNLAFLGIAYNTLL
★ *  ★  ★
iCreM24
RIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVAD 240
iCre-262-1
RIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVAD 240
iCre-2 62-21
RIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVAD 240
iCre-262-14
RIAEIARIRVKDISRTDGGRMLIHIGRTKTLVSTAGVEKALSLGVTKLVERWISVSGVAD 240
★ ★ ★ ★
iCreM24
DPNNYLFCRVRKNGVAAPSATSQLSTRALEGIFEATHRLIYGAKDDSGQRYLAWSGHSAR 300
iCre-262-1
DPNNYLFCRVRKNGVAAPSATSQLSTRALNGIFEATHRLIYGAKDDSGQRYLAWSGHSAR 300
iCre-262-21
DPNNYLFCRVRKNGVAAPSATSQLSTRALSGIFEATHRLIYGAKDDSGQRYLAWSGHSAR 300
iCre-262-14
DPNNYLFCRVRKNGVAAPSATSQLSTRALSGIFEATHRLIYGAKDDSGQRYLAWSGHSAR 300
★  ★ ★ ic
iCreM24
VGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGD 351
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iCre-262-1
VGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGD 351 
iCre-262-21
VGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGD 351 
iCre-262-14
VGAARDMARAGVSIPEIMQAGGWTNVNIVMNYIRNLDSETGAMVRLLEDGD 351 
★ ★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★★
Figure A.2: Protein sequence alignments of Cre-M24, Cre262-1, Cre262-14 and 
Cre262-21 using Clustal Omega software. The stars below the sequence indicate 
match in amino acids while a dot indicate a mutation in the protein sequence. The 
location of the amino acid can be determined by the numbers present at the end of 
the sequence.
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